drugset / Trial / NCT00255489

A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer

NCT00255489

Phase 1 Completed 36 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the safety profile of ZD1839 in combination with Palliative thoracic Radiotherapy in patients with non-small cell lung cancer

Timeline

Start
2004-05
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule